Neurocrine Biosciences (NBIX) Cash from Investing Activities (2010 - 2026)

Neurocrine Biosciences has reported Cash from Investing Activities for 17 years, with the latest figure at -$135.4 million in Q2 2026.

• Cash from Investing Activities for Q2 2026 came in at -$135.4 million, down 366.9% year-over-year; the trailing twelve-month figure through Jun 2026 was -$891.2 million (down 1426.03% YoY), and the FY2025 annual result was -$264.4 million, down 108.52% from the prior year.
• Cash from Investing Activities advanced to -$135.4 million in Q2 2026, from -$506.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $31.4 million in Q2 2022 and troughed at -$506.2 million in Q1 2026.
• A 5-year average of -$93.2 million and a median of -$58.2 million in 2022 frame the typical range for Cash from Investing Activities.
• The widest annual swing landed in 2022, when Cash from Investing Activities jumped 134.58%; it then plunged 3664.79% in 2026.
• A 5-year view of Cash from Investing Activities shows it stood at -$115.6 million in 2022, then tumbled by 74.57% to -$201.8 million in 2023, then surged by 66.15% to -$68.3 million in 2024, then increased by 22.55% to -$52.9 million in 2025, then sank by 155.95% to -$135.4 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$135.4 million in Q2 2026, -$506.2 million in Q1 2026, and -$52.9 million in Q4 2025.